North America Next-Generation Sequencing (NGS) Services Market (2017-2022)
The North America Next-Generation Sequencing (NGS) Services Market was valued at $456.2 Million in 2017 and projected to reach to $1171.7 Million by 2022, representing a compound annual growth rate of CAGR 20.8%. North America's NGS services market is poised for sustained expansion through 2022 and beyond, fueled by declining sequencing costs, increasing clinical adoption, and rising demand for genomic data in oncology, cardiology, and rare disease diagnosis.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
North America Next-Generation Sequencing (NGS) Services Market Trends and Insights
- This 20.8% compound annual growth rate reflects North America's leadership in genomic research, precision medicine adoption, and advanced diagnostic capabilities.
- North America's dominance is driven by substantial investments in healthcare infrastructure, high prevalence of genetic disorders, and strong demand for personalized treatment approaches across oncology, rare diseases, and reproductive health applications..
Key Market Statistics
- CAGR (2017-2022) CAGR 20.8%
- Market Size, 2017 ~USD 456.2 Million
- Forecast, 2022 ~USD 1171.7 Million
- Geography North America
North America Next-Generation Sequencing (NGS) Services Market Overview
Market Leadership Position :
North America commands the largest share of the global NGS services market, driven by substantial investments in genomic research infrastructure, leading academic institutions, and a concentration of biotechnology companies pioneering sequencing innovations.
Precision Medicine Adoption :
The region leads in integrating NGS into clinical diagnostics and personalized medicine workflows, with healthcare systems increasingly adopting sequencing for cancer genomics, rare disease diagnosis, and pharmacogenomics applications.
Robust Growth Trajectory :
North America's NGS services market is expanding at 20.8% CAGR from 2017–2022, outpacing many global regions and reflecting strong demand from pharmaceutical R&D, clinical laboratories, and research institutions.
Regulatory and Reimbursement Maturity :
Established regulatory frameworks (FDA oversight) and growing insurance reimbursement for NGS-based diagnostics in the U.S. and Canada provide a stable environment for market expansion and service provider growth.
North America Next-Generation Sequencing (NGS) Services Market Dynamics
- The region's advanced healthcare infrastructure, coupled with significant R&D spending by pharmaceutical and biotech firms, positions it as a global innovation hub for sequencing technologies and applications. Key growth drivers include expanding precision medicine initiatives, growing patient awareness of genetic testing, and integration of NGS into routine clinical practice.
- However, market players must navigate regulatory complexities, data privacy concerns, and the need for standardized interpretation protocols.
- Strategic partnerships between service providers, healthcare systems, and research organizations will be critical to capturing emerging opportunities in North America's competitive NGS landscape..
Market Ecosystem
NEXT-GENERATION SEQUENCING (NGS) SERVICES MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
Scientists studying Usutu virus sent viral nucleic acid to Eurofins Genomics for a dedicated RNA-virus sequencing service (INVIEW virus sequencing) on an Illumina NovaSeq 6000 to generate whole-genome data for analysis and comparison with other methods | Quick access to high-quality viral genomes | High-throughput sequencing without adding lab capacity | Supports surveillance and phylogenetics | Clean data for downstream bioinformatics |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
Related Ecosystem
Advanced Genetic Sequencing
- Polymerase Chain Reaction (PCR)
- Reagents
- Assay Kits
- Bioinformatics
- Flow Cytometry
- Thermo Fisher Scientific Inc.
- Illumina, Inc.
- Agilent Technologies, Inc.
- Qiagen N.V.
- Danaher Corporation
Key Takeaways
- North America's NGS Services Market is valued at $456.2 million in 2017 and is forecast to reach $1,171.7 million by 2022, representing a 20.8% CAGR.
- North America leads global NGS adoption due to advanced healthcare infrastructure, significant R&D investments, and strong reimbursement frameworks.
- North America's market growth is accelerated by increasing demand for precision medicine, cancer genomics, and non-invasive prenatal testing applications.
- North America's competitive landscape features established players and emerging biotech firms leveraging technological innovation to capture market share.
Next-Generation Sequencing (NGS) Services Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2017 |
| Fastest Growing Segment | AGRICULTURE & ANIMAL RESEARCH (Application) |
| Forecast Period | 2017–2022 |
| Growth Rate | CAGR of 21% from 2017 to 2022 |
| Largest Segment | DIAGNOSTICS (Application) |
| Market Size Base Year (Billions) | ~USD 1.06 (2017) |
| Revenue Forecast (Billions) | ~USD 2.748 (2022) |
| Segments Covered | Type, Application, End User, Technology |
North America Next-Generation Sequencing (NGS) Services Market Report Segmentation
4 segment dimensions are covered across the global market.
By Type
- Chip-Seq
- De Novo Sequencing
- Exome Sequencing
- Methyl-Seq
- Other Ngs Services
- Other Services
- Rna-Seq
- Targeted Sequencing/Custom Gene Panels
- Targeted Sequencing/Gene Panels
- Whole-Genome Sequencing
By Application
- Agriculture & Animal Research
- Biomarker Discovery
- Diagnostics
- Drug Discovery
- Infectious Diseases
- Oncology
- Other Applications
- Other Applications*
- Other Diagnostic Applications
- Rare Genetic Disorders
- Reproductive Health
By End User
- Academic & Government
- Academic & Government Institutes And Research Centers
- Hospitals & Clinics
- Other End Users
- Other End Users*
- Pharmaceutical & Biotechnology Companies
By Technology
- Ion Semiconductor Sequencing
- Nanopore Sequencing
- Sequencing By Synthesis
- Single-Molecule Real-Time Sequencing
Target Audience
- Pharmaceutical & Biotech Companies : Need comprehensive market data to guide R&D investments, clinical trial design, and companion diagnostic development strategies in North America's rapidly expanding NGS services ecosystem.
- Clinical Laboratory Operators : Require market sizing, competitive benchmarking, and adoption trend analysis to inform service expansion, technology investments, and pricing strategies in the U.S. and Canadian markets.
- Healthcare Systems & Hospital Networks : Seek insights on NGS integration into clinical workflows, reimbursement models, and patient demand forecasts to justify capital expenditures and operational planning for genomic medicine programs.
- Sequencing Technology Vendors : Need regional market intelligence on end-user demand, competitive positioning, and emerging applications to optimize product development, sales strategies, and market penetration in North America.
- Investment & Strategy Consultants : Require detailed market analysis, growth projections, and regional dynamics to advise clients on M&A opportunities, market entry strategies, and portfolio optimization in the NGS services sector.
Key Companies in the North America Next-Generation Sequencing (NGS) Services Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| ILLUMINA, INC. | United States | Public Company | Targeted sequencing services,RNA-Seq services,Exome sequencing services, |
| PERKINELMER, INC. | United States | Public Company | Targeted sequencing services,RNA-Seq services,Exome sequencing services, |
| EUROFINS SCIENTIFIC SE | Luxembourg | Public Company | Targeted sequencing services,RNA-Seq services,Exome sequencing services, |
| MACROGEN, INC. | South Korea | Public Company | Targeted sequencing services,RNA-Seq services,Exome sequencing services, |
| QIAGEN N.V. | Netherlands | Public Company | Targeted sequencing services (panels, amplicon, gene panels),RNA-Seq services,Exome and de novo sequencing services, |
| DNA LINK, INC. | South Korea | Public Company | Whole genome & De Novo sequencing services,Whole exome & targeted sequencing services,Transcriptome & single-cell RNA sequencing, |
| TAKARA BIO INC. (PART OF TAKARA HOLDING COMPANY INC.) | Japan | ||
| NOVOGENE CORPORATION | China | Public Company | Whole genome and targeted sequencing services (incl. human/animal/plant/microbial WGS and targeted panels),Transcriptomics and single-cell sequencing (mRNA, lncRNA, small RNA, single-cell, spatial),De novo, metagenomics, and microbiome sequencing, |
| PERSONALIS, INC. | United States | Public Company | Oncology MRD and monitoring (NeXT Personal, NeXT Personal Dx),Comprehensive tumor profiling (ImmunoID NeXT, NeXT Dx),Population and research sequencing (WES/WGS services), |
ILLUMINA, INC.
Illumina, Inc. is a public company founded in 1998 and headquartered in the United States with 8,625 employees. The company is a leader in DNA sequencing and genetic analysis technologies.
PERKINELMER, INC.
PerkinElmer, Inc. is a public company founded in 1937 and based in the United States with 11,000 employees. The company provides diagnostic and research solutions across life sciences and environmental testing.
EUROFINS SCIENTIFIC SE
Eurofins Scientific SE is a public company founded in 1987 and headquartered in Luxembourg with 65,694 employees. The company operates a network of laboratories providing testing and analytical services across multiple industries.
MACROGEN, INC.
Macrogen, Inc. is a public company founded in 2000 and based in South Korea with 293 employees. The company provides genomic research services including DNA sequencing and analysis.
QIAGEN N.V.
QIAGEN N.V. is a public company founded in 1984 and headquartered in the Netherlands with 5,500 employees. The company develops and manufactures molecular diagnostics and life sciences tools.
DNA LINK, INC.
DNA Link, Inc. is a public company founded in 2000 and based in South Korea with 84 employees. The company offers genomic analysis and genetic testing services.
TAKARA BIO INC. (PART OF TAKARA HOLDING COMPANY INC.)
Takara Bio Inc. is a company based in Japan and operates as part of Takara Holding Company Inc. The company specializes in biotechnology and life sciences research products.
NOVOGENE CORPORATION
Novogene Corporation is a public company founded in 2011 and based in China with 2,225 employees. The company provides genomic sequencing and bioinformatics analysis services.
PERSONALIS, INC.
Personalis, Inc. is a public company founded in 2011 and based in the United States with 260 employees. The company develops genomic testing and analysis solutions for precision medicine.
Countries within North America - compare and drill down
| Country | 2025 size (native) |
|---|---|
| U.S. | USD 1149.2 Million |
| Canada | USD 22.5 Million |
Country market size visualization
Reasons to Buy this Report
- Regional Market Sizing & Forecasts : Obtain precise market valuations for North America ($456.2M in 2017, $1,171.7M by 2022) with country-level breakdowns for the U.S. and Canada, enabling accurate business planning and investment decisions.
- Competitive Landscape Intelligence : Understand the competitive dynamics specific to North America's NGS services sector, including key players, market consolidation trends, and differentiation strategies in this high-growth region.
- Clinical Adoption & Reimbursement Insights : Access detailed analysis of NGS adoption rates across North American healthcare systems, insurance reimbursement trends, and regulatory pathways that directly impact market penetration and revenue potential.
- Growth Driver Analysis : Identify region-specific growth catalysts including precision medicine initiatives, pharmaceutical R&D spending, academic research funding, and emerging clinical applications driving the 20.8% CAGR.
- Strategic Market Entry & Expansion : Leverage North America-focused market intelligence to develop targeted go-to-market strategies, identify partnership opportunities, and optimize resource allocation for service providers and technology vendors.
Frequently asked questions
What is the market size of NGS Services in North America?
North America's NGS Services Market was valued at $456.2 million in 2017 and is projected to reach $1,171.7 million by 2022.
What is the growth rate of the NGS Services Market in North America?
North America's NGS Services Market is expected to grow at a compound annual growth rate (CAGR) of 20.8% from 2017 to 2022.
What factors are driving NGS Services growth in North America?
North America's NGS market growth is driven by increasing adoption of precision medicine, rising cancer incidence, growing demand for non-invasive prenatal testing, and strong healthcare reimbursement policies.
Which applications dominate the NGS Services Market in North America?
North America's NGS Services Market is dominated by oncology, rare disease diagnosis, reproductive health testing, and infectious disease identification applications.
Who are the key players in North America's NGS Services Market?
North America's NGS Services Market includes major players such as Illumina, Thermo Fisher Scientific, 10x Genomics, and numerous specialized genomic service providers and clinical laboratories.
RESEARCH METHODOLOGY
This study on the Next-Generation Sequencing (NGS) Services Market employed secondary sources, directories, and databases to gather pertinent information. To gather and validate important qualitative and quantitative data and evaluate market growth prospects, in-depth interviews were conducted with many primary respondents including key industry participants, subject-matter experts (SMEs), C-level executives from key market players, and industry consultants. After estimating the Next-Generation Sequencing (NGS) Services Market using several research strategies, the size of the final market was obtained by triangulating data from primary research.
Secondary Research
The secondary sources referred to for this research study include publications from government sources. These include the Centers for Disease Control and Prevention (CDC), the US Food and Drug Administration (FDA), the World Health Organization (WHO), the American Cancer Society (ACS), the National Center for Biotechnology Information (NCBI), the National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI), International Agency for Research on Cancer (IARC), National Institute for Infectious Diseases (IRCCS), Association for Clinical Genomic Science (ACGS), American Society of Human Genetics (ASHG), European Society of Human Genetics (ESHG), Asia Pacific Society of Human Genetics (APSHG), Nature Reviews Genetics, Nature Methods, Biotechnology and Biological Sciences Research Council (BBSRC), Organisation for Economic Co-operation and Development (OECD), Genome Research, National Cancer Institute (NCI), European Medicines Agency (EMA), Population Health Research Institute (PHRI), PubMed, World Bank, and the World Health Organization (WHO), among others. Secondary sources also included corporate & regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines & research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global Next-Generation Sequencing (NGS) Services Market , which was validated through primary research.
Primary Research
Extensive primary research was conducted after acquiring basic knowledge about the global Next-Generation Sequencing (NGS) Services Market scenario through secondary research. Several primary interviews were conducted with market experts from the supply side, such as C-level and D-level executives, operational managers, marketing & sales managers of key manufacturers, distributors, and channel partners of companies providing NGS; experts from the demand side, such as personnel from academic & research institutes, hospitals, clinics and diagnostic labs, pharmaceutical & biopharmaceutical industries, CROs, and other end users. These interviews were conducted across six major regions, including North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa. Approximately 70% and 30% of the primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the Next-Generation Sequencing (NGS) Services Market . These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
Data Triangulation
To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
NGS refers to non-Sanger-based, high-throughput DNA sequencing technologies. DNA strands can be sequenced simultaneously, yielding substantially more throughput and minimizing the need for fragment-cloning methods often used in the Sanger sequencing of genomes. NGS is fundamentally based on sequencing by synthesis (SBS), ion semiconductor sequencing, single-molecule real-time (SMRT) sequencing, and nanopore sequencing.
Stakeholders
- NGS instrument manufacturers, vendors, and distributors
- NGS service providers
- NGS bioinformatics/data analysis companies
- Research laboratories and academic institutes
- Venture capitalists and other government funding organizations
- Research and consulting firms
- Healthcare institutions (hospitals and diagnostic clinics)
- Pharmaceutical and biotechnology companies
- Academic and government research institutes
- Life science companies
Report Objectives
- To define, describe, and forecast the Next-Generation Sequencing (NGS) Services Market based on offerings, product type, platform technology, product workflow, product end user, service type, service workflow, service end user, application, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micro markets with respect to individual growth trends, prospects, and contributions to the overall next-generation sequencing market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
- To profile the key players in the global Next-Generation Sequencing (NGS) Services Market and comprehensively analyze their platforms, reagents, kits, consumables, and services portfolios, market positions, and core competencies
- To track and analyze competitive developments such as product & service launches, expansions, agreements, and collaborations in the next-generation sequencing market
- To benchmark players within the Next-Generation Sequencing (NGS) Services Market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and service strategy
Get the Full Next-Generation Sequencing (NGS) Services Market Report
Full forecast, segment splits, and company analysis for all Next-Generation Sequencing (NGS) Services Market.
- Canada Next-Generation Sequencing (NGS) Services Market
- Germany Next-Generation Sequencing (NGS) Services Market
- France Next-Generation Sequencing (NGS) Services Market
- China Next-Generation Sequencing (NGS) Services Market
- Japan Next-Generation Sequencing (NGS) Services Market
- India Next-Generation Sequencing (NGS) Services Market
- U.S. Next-Generation Sequencing (NGS) Services Market
- Roe Next-Generation Sequencing (NGS) Services Market
- U.K. Next-Generation Sequencing (NGS) Services Market
- Roapac Next-Generation Sequencing (NGS) Services Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
